Jeopardy: Update on Diabetes Pharmacotherapy Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University Chicago College of Pharmacy Objectives Describe the mechanism of action and unique features of the 6 classes of medications that are recommended by the ADA as second line therapies for type 2 diabetes. Discuss contraindications and side effect considerations when recommending second line therapies for type 2 diabetes. Given a patient case where the patient has reached the maximal dosage of metformin, select among second line treatment options for individualize care. Why is Glucose Control Important? 60% of people with type 2 diabetes have at least 1 complication because of diabetes Complications are often present at time of diagnosis AACE. State of diabetes complications in America. 2007. http://multivu.prnewswire.com/mnr/aace/2007/docs/diabetes_complications_report.pdf (accessed 2016 Aug 20). 1
β cell Decline in Prediabetes and T2DM Change in insulin / change glucose / IR IR = insulin resistance Normal glucose tolerance Impaired glucose tolerance Type 2 diabetes DeFronzo RA. Diabetes. 2009; 58:773 95. The Ominous Octet: Circa 2008 Brain Pancreas ß cell Pancreas α cell Liver GI tractstomach/small intestine Hyperglycemia Kidney Peripheral tissue muscle e Fat cells (adipose tissue) Cornell S et al. Postgrad Med. 2012; 124:84 94. Defronzo RA. Diabetes. 2009; 58:773 95. Treatment Approach to T2DM Dietary changes Reduce consumption of calories Reduce consumption of simple carbohydrates Increase physical activity Medications Improve or replace insulin secretion Reduce insulin resistance Reduce glucagon secretion Reduce hepatic glucose production Increase urinary glucose excretion DeFronzo RA et al. Diabetes Care. 2013; 36(suppl 2):S127 38. 2
12 Pharmacotherapy Options Insulin (1) Bolus insulin Insulin lispro U100 U200 Insulin aspart Insulin glulisine Insulin human inhaled Regular human insulin Basal insulin Insulin NPH Insulin detemir Insulin degludec U100 U200 Insulin glargine U100 U300 Oral Medications (9) -glucosidase inhibitors (AGI) Biguanides Bile acid sequestrants (BAS) Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) Dopamine agonists Glinides Sulfonylureas (SU) Sodium Glucose Co-Transporter-2 inhibitors (SGLT-2i) Thiazolidinediones (TZDs or glitazones) Non-insulin injectable agents (2) Glucagon-like peptide-1 (GLP-1) agonists Amylinomimetic Cornell S et al. Postgrad Med. 2012;124:84-94. www.pdr.net (accessed 2016 June 30).. ADA Standards of Medical Care in Diabetes (2015) Inzucchi SE et al. Diabetes Care. 2015; 38:140 9. Garber AJ. Endocr Pract. 2016; 22:84 113. 3
Oral Agents Metformin: Current Cornerstone of Therapy Affordable Possible weight loss benefit Low risk of hypoglycemia GI side effects can be managed Risk of lactic acidosis far less than feared Effectively lowers BG and A1c Though not sustainable as monotherapy Rational Choices for second line add on to Metformin Drugs that target different metabolic defects Combine medications that work at different tissue sites for synergy Drugs that target fasting and postprandial glucose control Select therapies that support patient goals Low hypo risk Weight neutral, loss 4
Sulfonylureas Glimepiride Amaryl 1mg, 2mg, 4mg Once daily Glipizide Glucotrol 5mg, 10mg Once to twice daily Glucotrol XL 2.5mg, 5mg, 10mg Once daily Glyburide Micronase 1.25mg, 2.5mg, 5mg Once to twice daily Diabeta 1.25mg, 2.5mg, 5mg Once to twice daily Glynase 1.5mg, 3mg, 6mg Once to twice daily Sulfonylureas: 1 st Generation Titrate every 2-4 weeks based on FPG Sulfonylureas Stimulates insulin release from the pancreas Long acting stimulation (>6 hours) Requires endogenous insulin to be affective; therefore better used early in the disease; if necessary Short durability Lowers fasting and postprandial glucose Decreases A1c by 1.5 2% (~45 60 mg/dl) Most common side effects Hypoglycemia Weight gain may inhibit ischemic pre conditioning Cornell S, Lullo A. Diabetes Trends 2009. 5
Meglitinides Repaglinide Prandin 0.5mg, 1mg, 2mg Up to three times daily before meals Nateglinide Starlix 60mg, 120mg Up to three times daily before meals Glinides Stimulates insulin release from the pancreatic beta cells Short acting stimulation (30 minutes to 4 hours) Requires endogenous insulin to be affective; therefore better used early in the disease; if necessary Short durability Lowers postprandial glucose Decreases A1c by 0.5 1% (~15 30 mg/dl; more postprandial) Most common side effects Hypoglycemia Weight gain Cornell S, Lullo A. Diabetes Trends 2009. TZD s (Glitazones) Pioglitazone Actos 15mg, 30mg, 45mg Once daily Rosiglitazone Avandia 2mg, 4mg, 8mg Once to twice daily 6
TZD s (Glitazones) Stimulates PPRA γ to increase GLUT 4 transporter production; thereby moving glucose from the blood into the peripheral tissue. Also reduces adipose fat Can be used thru duration provided insulin is present Good durability Lowers fasting and postprandial glucose Decreases A1c by 1.0 1.5% (~30 45 mg/dl) Most common side effects Edema (swelling) usually in the legs Weight gain Possible risk of fractures. Takes 4 6 weeks (or more) to take affect and requires insulin (endogenous or exogenous) Cornell S, Lullo A. Diabetes Trends 2009. DPP4 Inhibitors (gliptins) Sitagliptin (Januvia ) 25 mg, 50 mg, & 100 mg Once daily dosing Dose adjustment in renal impairment Saxagliptin (Onglyza ) 2.5 mg & 5 mg Once daily dosing Dose adjustment in renal impairment Linagliptin (Tradjenta ) 5 mg Once daily dosing Alogliptin (Nesina ) 6.25 mg, 12.5 mg, & 25 mg Once daily dosing Dose adjustment in renal impairment DPP4 Inhibitors (gliptins) Inhibits DPP 4 enzyme in the GI tract that breaks down GLP 1 resul ng in endogenous GLP 1. glucagon suppression (from pancreatic alpha cell) results in liver glucose production Enhances appropriate insulin and amylin secretion from the pancreatic beta cells Can be used thru duration provided insulin is present Promising durability Lowers postprandial glucose Decrease A1c by 0.5 to 0.7% ( ~15 20 mg/dl; most postprandial) Most common side effects Stuffy, runny nose Headache Upper respiratory tract infection Cornell S. Dorsey VJ. Postgraduate Medicine. 2012;124(4):84-94. 7
Sodium Glucose Co Transporter 2 Inhibitors (SGLT 2i) Canagliflozin Invokana 100mg & 300mg taken once daily before first meal of the day. Dapagliflozin Farxiga 5mg & 10mg taken once daily (ideally, before first meal of the day). Empagliflozin Jardiance 10mg & 25mg taken once daily (ideally, before first meal of the day). Sodium Glucose Co Transporter 2 Inhibitors (SGLT 2i) renal glucose reabsorption in the early proximal tubule of the kidney Possibly reduces adipose fat likely due to water and fat urina on (elimination) Lowers fasting glucose Decreases A1c by 0.7 1% (~20 30 mg/dl) Most common side effects Weight loss Vaginal and male genital infections Rash UTI Frequent urination Increased thirst GI problems (when combined with metformin) List JF, et al. Diabetes Care. 2009;32(4):650-657. Wilding JP, et al. Diabetes Care. 2009;32(9):1656-1662. SGLT2 Inhibitors: Comparisons Canagliflozin Dapagliflozin Empagliflozin Efficacy (A1c lowering) Monotherapy 0.77 1.03% 0.8 0.9% 0.7 0.8% Combination 0.79 0.94% 0.7 0.8% 0.7 0.8% Dose and Frequency 100 300 mg once daily 5 10 mg once daily 10 25 mg once daily Renal dose adjustment CrCl <60 ml/min 100 mg once daily Use not *No dosage recommended adjustment CrCl <45 ml/min Use not recommended Invokana (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2013. Farxiga (dapagliflozin) [package insert]. Princeton, NJ: Bristol Myers Squibb Company; August 2014. Jardiance (empagliflozin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014. 8
Injectable Agents GLP 1 Agonists short acting GLP 1 agonists Exenatide (Byetta ) 5 mcg & 10 mcg Twice daily dosing Lixisenatide (Adlyxin ) 10 mcg & 20 mcg once daily dosing long acting GLP 1 agonists Liraglutide (Victoza ) 0.6 mg, 1.2 mg, & 1.8 mg Once daily dosing Exenatide (Bydureon ) 2 mg Once weekly dosing Albiglutide (Tanzeum ) 30mg & 50mg Once weekly dosing Dulaglutide (Trulicity ) 0.75 mg & 1.5 mg Once weekly dosing GLP 1 Agonists GLP 1 agonists fix 5 dysfunctional organs in T2DM glucagon suppression from the pancreatic alpha cell Results in liver glucose production Enhances appropriate insulin and amylin secretion from the pancreatic beta cell Results in brain satiety Regulates the GI tract to slow gastric emptying time Can be used thru duration provided insulin is present Promising durability Short acting agonists lowers postprandial glucose Decreases A1c by 0.8 1.5% (~20 45 mg/dl; most postprandial) Long acting agonists lowers fasting and postprandial glucose Decreases A1c by 0.8 1.8% (~20 50 mg/dl) Most common side effects Weight loss Stomach upset Caution in patients at risk for pancreatitis Cornell S. Dorsey VJ. Postgraduate Medicine. 2012;124(4):84-94. 9
Differences in GLP 1 agonists Exenatide BID Lixisenatide Liraglutide Exenatide QW Albiglutide Dulaglutide Dose 5 & 10 mcg BID (within 30 60 min of am/pm meal) 10 & 20 mcg (within 60 min of same meal once daily) 0.6 mg initial, then to 1.2 & 1.8 mg Once daily, anytime 2 mg weekly 30mg & 50mg weekly 0.75 mg & 1.5 mg weekly Max dose 10 mcg BID 20 mcg daily 1.8 mg daily 2mg weekly 50 mg weekly 1.5 mg weekly Half life 2 4 hours 2 4 hours 13 hours 5 days 5 days 5 days Homology to GLP 1 53% 50% 97% 53% 97% 90% Antibodies 44% 69.8% 8.6% 44% 2.5% 2% FPG or PPG effects PPG PPG Both, FPG & PPG Both, FPG & PPG Both, FPG & PPG Both, FPG & PPG FPG = fasting plasma glucose; PPG = postprandial plasma glucose High Concentration or Low Volume Glargine (U300) Available only in a pen U 300: 450 units/pen, max 80 units/inj Can be used for patients on small and large volumes of insulin Offers a smaller depot surface area, leading to a reduced rate of absorption Provides flatter and prolonged pharmacokinetic and pharmacodynamic profiles and more consistency Half life is ~23 hours Steady state in 4 days Duration of action 36 hours 1. Garber AJ. Diabetes Obesity Metab; published online 31 Oct 2013]. 2. Owens DR, et al. Diabetes Metab Res Rev. 2014;30(2):104 19. 3. Steinstraesser A, et al. Diabetes Obes Metab. 2014 Feb 26.. PK and PD of U300 Insulin Glargine vs U100 Insulin Glargine 1 U300 glargine displays a more even and prolonged PK/PD profile compared with U100 glargine, offering blood glucose control beyond 24 hours INS [µu/ml 1 ] GIR [mg/kg 1 /min 1 ] 25 20 15 10 5 0 3 2 1 0 LLOQ 0 6 12 18 24 30 Time (h) Gla 100 0.4 U/kg 1 Gla 300 0.4 U/kg 1 N=30 36 1. Becker RH, et al. Diabetes Care. 2014;pii:DC_140006. 10
U 100 and U 200 Insulin Degludec Available only in a pen U 200: 600 units/pen, max 160 units/inj U 100: 300 units/pen, max 80 units/inj Can be used for patients on small and larger volumes of insulin Provides flatter and prolonged pharmacokinetic and pharmacodynamic profiles and more consistency Duration of action >42 hours Half life ~25 hours Detectable for at least 5 days Steady state in 3 4 days 1. Garber AJ. Diabetes Obesity Metab; published online 31 Oct 2013]. 2. Owens DR, et al. Diabetes Metab Res Rev. 2014;30(2):104 19. Glucose Infusion Rate 5 4 3 Basal Insulin Degludec Flat, stable profile of both 100 unit/ml and 200 unit/ml formulations Mean 24 Hour GIR Profile of the Two Insulin Degludec Formulations at Steady State IDeg 100 U/mL 0.8 U/kg IDeg 100 U/mL 0.6 U/kg IDeg 100 U/mL 0.4 U/kg IDeg 200 U/mL 0.6 U/kg Half life at Steady State IDeg 200 U/mL 0.6 U/kg Mean Half life (hours) 26.2 h 2 n = 21 n = 37 1 n = 16 n = 22 0 Day 6 Day 7 GIR = glucose infusion rate. 1. Heise T, et al. ADA. 2012, Oral 349 Abstract (Trial: NN1250 1987). 2. Nosek L, et al. IDF 2011: P 1452; Diabetologia. 2011;54(suppl. 1):S429 (1055 P); Diabetes. 2011;60(suppl. 1A):LB14. Side Effects and Contraindications 11
Frequently Reported ADEs in Patients Receiving a DPP 4i Adverse Reactions Reported Core Phase 3 Placebo-Controlled Studies, %* Adverse Reaction Sitagliptin 100 mg 1 Saxagliptin 2.5 mg 2 Saxagliptin 5 mg 2 Linagliptin 5 mg 3 Alogliptin 25 mg 4 Headache 5.1 5.9 6.5 6.5 4.2 Nasopharyngitis 5.2 6.3 7.0 4.4 URTI 5.5 6.3 7.7 4.2 UTI 6.8 *Excluding hypoglycemia. Data from multiple core studies. Pooled data from core studies. URTI = upper respiratory tract infection; UTI = urinary tract infection. No differences in the overall safety profiles of the various DPP-4 inhibitors have so far emerged. 5 1. Januvia (sitagliptin). Prescribing information. 2. Onglyza (saxagliptin). Prescribing information.. 3. Tradjenta (linagliptin). Prescribing information. 4. Nesina (alogliptin). Prescribing information. 5. Deacon. Diabetes Obes Metab. 2011;13:7 18. Pharmacologic and PK Characteristics of DPP 4i Approximate ex Vivo DPP-4 Inhibition, % 1 24 H Agent Maximum Postdose Metabolism Elimination Sitagliptin 97 80 Not appreciably Primarily renal (~79% metabolized 2 excreted unchanged by kidney) 2 Saxagliptin 80 70 Hepatically transformed to active metabolite, chiefly by CYP3A4/5 3 Linagliptin 80 70 ~90% eliminated unchanged; exposure decreased by strong CYP3A4 or P-gp inducers 4 Primarily renal (24% as parent compound, 36% as metabolite); also hepatic 3 Primarily enterohepatic (80%); renal, 5% 4 Alogliptin 90 75 Not appreciably Primarily renal (up to 71% metabolized 5 excreted unchanged by kidney) 5 CYP = cytochrome P450; P-gp = P-glycoprotein. 1. Deacon. Diabetes Obes Metab. 2011;13:7 18. 2. Januvia (sitagliptin). Prescribing information.. 3. Onglyza (saxagliptin). Prescribing information. 4. Tradjenta (linagliptin). Prescribing information.. 5. Nesina (alogliptin). Prescribing information. Safety Issues with DPP 4i Rare cases of acute pancreatitis and HSRs have been reported during clinical trials and the postmarketing period 1 5 Acute pancreatitis Meta analysis did not detect increased incidence vs comparators in core trials 5 Patients should be monitored for signs and symptoms, especially at start of therapy 1,2,4 If pancreatitis is suspected, DPP 4 inhibitor should be discontinued promptly and management initiated 1,2,4 HSRs Often occur within first 3 months of treatment 1,2 Discontinue agent and do not restart if serious HSR is suspected 1 4 Use caution when prescribing a DPP 4 inhibitor for a patient who had a HSR during treatment with a previous DPP 4 inhibitor 1,2,4 HSR = hypersensitivity reaction. 1. Januvia (sitagliptin). Prescribing information. 2. Onglyza (saxagliptin). Prescribing information. 3. Tradjenta (linagliptin). Prescribing information. 4. Nesina (alogliptin). Prescribing information. 5. Monami et al. Curr Med Res Opin. 2011;27:57 64. 12
GLP-1 agonist : GI Adverse Events Incidence of Adverse Event, % Head-to-Head Trial, Active Comparators Nausea Vomiting Diarrhea LEAD-6: liraglutide 1.8 mg, exenatide 10 μg 26, 28 6, 10 12, 12 DURATION-1: exenatide extended release 2 mg, exenatide 10 μg 26, 35 11, 19 14, 13 DURATION-5, exenatide extended release 2 mg, exenatide 10 μg 14, 35 5, 9 9, 4 DURATION-6, exenatide extended release 2 mg, liraglutide 1.8 mg 9, 21 4, 11 6, 13 HARMONY-7, albiglutide 50 mg, liraglutide 1.8 mg 10, 29 5, 9 15, 14 AWARD-1, dulaglutide 0.75 & 1.5 mg, exenatide 10 μg 16, 28, 26 6, 17, 11 8, 11, 6 AWARD-6, dulaglutide 1.5 mg, liraglutide 1.8 mg 20, 18 7, 8 12, 12 In clinical practice, GI disturbances often resolve over time, but 5 10% of patients discontinue treatment due to adverse effects. Following dose titration instructions reduces risk of GI disturbances. Patients with preexisting severe GI disease (eg, gastroparesis) should not use a GLP-1 agonists. Buse. Lancet. 2009. Drucker. Lancet. 2008. Blevins. J Clin Endocrinol Metab. 2011. Buse. Lancet. 2013. Pratley. Lancet Diabetes Endocrinol. 2014. Wysham. Diabetes Care. 2014. Dungan. Lancet. 2014. Handelsman. Endocr Pract. 2015. Pancreatic Safety for GLP-1 agonists Pancreatitis has been reported in association with GLP-1 agonist treatment Until more is known, providers should Observe patients carefully for pancreatitis signs and symptoms Discontinue agent if pancreatitis is suspected Not restart treatment if pancreatitis is confirmed Consider other glucose-lowering agents in patients with pancreatitis history Byetta. PI. Feb. 2015. Victoza. PI. Mar. 2015. Bydureon. PI. Mar. 2015. Tanzeum. PI. Mar. 2015. Trulicity. PI. Mar. 2015. Egan. N Engl J Med. 2014. Butler. Diabetes Care. 2013. Thyroid C-Cell Tumors Currently unknown whether GLP-1 agonists cause thyroid C-cell tumors in humans Liraglutide, exenatide extended release, albiglutide, and dulaglutide Have boxed warning on thyroid C-cell tumor risk Are contraindicated in patients with personal or family history of MTC and in patients with MEN 2 Prescribers should Counsel patients about potential MTC risk Inform them about thyroid tumor symptoms Stipulations do not apply to exenatide (twice daily) MEN 2 = multiple endocrine neoplasia syndrome type 2; MTC = medullary thyroid carcinoma Byetta. PI. Feb. 2015. Victoza. PI. Mar. 2015. Bydureon. PI. Mar. 2015. Tanzeum. PI. Mar. 2015. Trulicity. PI. Mar. 2015. 13
Comparing the Effects of GLP 1 Agonists and DPP 4i Effect 1 GLP-1 Agonists DPP-4 Inhibitors Increase beta-cell mass and proliferation ++ + Reduce beta-cell apoptosis ++ + Enhance glucose-dependent insulin secretion ++ + Reduce hepatic glucose production ++ + Improve fasting glucose ++ + Improve postprandial glucose ++ + Delay gastric emptying ++ Increase satiety and reduce food intake ++ Promote weight loss ++ GLP-1 agonists are administered by subcutaneous injection; DPP-4 inhibitors are administered orally. = negligible effects; + = modest effects; ++ = pronounced effects. 1. Cornell. J Clin Pharm Ther. 2012;37:510 524. SGLT 2 Inhibitors Adverse Effects Most common side effects Weight loss Vaginal and male genital infections Rash UTI Frequent urination Increased thirst GI problems (when combined with metformin) List JF et al. Diabetes Care. 2009; 32:650-7. Wilding JP et al. Diabetes Care. 2009; 32:1656-62. SGLT 2i Weight Effects Meta analysis Mean difference Upper 95% CI Lower 95% CI Canagliflozin 0.640 0.768 0.513 Dapagliflozin 0.592 0.692 0.491 Empagliflozin 0.564 0.745 0.384 SUMMARY 0.591 kg 0.663 0.519 P<0.001 Mechanism: 1 gram glucose = 4 kcal. Loss of potentially 200 300 kcal/day Maximum weight loss at approximately 6 months Weight loss is, in general, maintained Berhan A et al. BMS Endocr Disord. 2013; 13:58 69. 14
SGLT 2i Blood Pressure Meta analysis Mean 95% CI Systolic BP SGLT2i vs. placebo 3.77 4.65 to 2.90 SGLT2i vs. active comparator 4.45 5.73 to 3.18 Diastolic BP SGLT2i vs. placebo 1.75 2.27 to 1.23 SGLT2i vs. other antidiabetics 2.01 2.62 to 1.39 Odds Ratio Hypotension 2.68 114 to 6.29 BP Lowering Mechanism Not fully determined but likely due to osmotic diuresis Orthostatic changes possible upon initiation Early 24 48 hour increased sodium excretion Caution in combination with other diuretics Vasilakou D et al. Ann Int Med. 2013; 159:262-74. CV Effects of DPP 4i, GLP 1 agonists and SGLT 2I Results of CV Outcomes Trials in T2DM Drug Class Study Drug vs. placebo N Results (year published) DPP 4i EXAMINE Alogliptin 5400 Neutral (2013) SAVOR TIMI Saxagliptin 16500 Neutral (2013) TECOS Sitagliptin 14000 Neutral (2015) CARMELINA Linagliptin 8300 Expected (2017) GLP 1 agonist ELIXA Lixisenatide 14000 Neutral (2015) LEADER Liraglutide 16500 Positive (2016) EXSCEL Exenatide QW 5400 Expected (2018) REWIND Dulaglutise 8300 Expected (2019) SGLT 2i EMPA REG Empagliflozin 7300 Positive (2015) CANVAS Canagliflozin 4300 Expected (2017) DECLARE dapagliflozin 22200 Expected (2019) DPP4i = dipeptidyl peptidase 4 inhibitor GLP 1 = glucagon like peptide 1 SGLT 2i = sodium glucose cotransporter 2 inhibitor Adapted from: Handelsman Y. Endocrine Today. 2016 15
LEADER Results 9340 patients randomized and followed for 3.8 years. Fewer patients died from CV causes in the liraglutide group (219 patients) than in the placebo group (278) P=0.007. The rate of death from any cause was lower in the liraglutide group (381 patients) than in the placebo group (447) P=0.02. The rates of nonfatal MI, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group. Is this reproducible? Is this a class effect? Will this change guideline recommendations? Marso S et al. N Engl J Med 2016; 375:311 322 EMPA REG Results 7300 randomized to empagliflozin vs. placebo. Primary outcome was 3 point MACE: Time to first occurrence of CV death, non fatal MI or non fatal stroke Key secondary outcome was 4 point MACE: Same as primary + hospitalization for unstable angina Treatment duration 2.6 years, Observation time 3.2 years Results were impressive and unexpected CV death by 38% all cause mortality by 32% heart failure hospitaliza on by 35% Number Needed to Treat to prevent one death in 3 years = 39 Is this reproducible? Is this a class effect? Will this change guideline recommendations? Zinman B, et al. NEJM 2015. Dosing Considerations 16
Biguanides (Metformin) Decreases liver glucose production Can be used throughout duration of disease; if no contraindication Good durability Lowers fasting glucose Decreases A1c by 1.5 2% (~45 60 mg/dl) Most common side effects Stomach and intestine distress May reduce B 12 levels after long term use Favorable lipid profile improvements good cholesterol (HDL) bad cholesterol (LDL) & ugly cholesterol (triglycerides). Caution in patients with renal & hepatic dysfunction CrCl < 1.4 in women and < 1.5 in men Cornell S, Lullo A. Diabetes Trends 2009. Metformin: Labeling changes egfr between 30 to 45 ml/minute/1.73 m 2. Not recommended egfr below 30 ml/minute/1.73 m 2 Contraindictaed If a patient is already on metformin egfr falls below 45 ml/minute/1.73 m 2, Weigh benefits of continuation verse discontinuation. egfr falls below 30 ml/minute/1.73 m 2 Discontinue metformin Sulfonylureas Stimulates insulin release from the pancreatic beta cell Long acting stimulation (>6 hours) Requires endogenous insulin to be affective; therefore better used early in the disease; if necessary Short durability Most common side effects Hypoglycemia Weight gain may inhibit ischemic pre conditioning Cornell S, Lullo A. Diabetes Trends 2009. 17
Pharmacologic and Pharmacokinetic Differences among GLP 1 Agonists Agent Dose Frequency and Timing t max t 1/2 Initial Dose (Duration) Regular Dose Elimination Exenatide BID BID; within 60 minutes before morning and evening meals 2.1 hours 2.4 hours 5 µg (1 month) 5 µg or 10 µg Mainly renal; not recommended for patients with ESRD or severe renal impairment Liraglutide QD; any time of day 8-12 hours 13 hours 0.6 mg (1 week) 1.2 mg or 1.8 mg Mainly metabolized by proteolytic degradation; use caution in patients with renal impairment Exenatide QW QW; timing not specified 2-7 weeks N/A 2 mg 2 mg Renal Albiglutide QW; timing not specified 3-5 days 6-7 days 30 mg 30 mg N/A Dulaglutide QW; timing not specified ~70 hours ~4 days N/A 0.75 mg or 1.5 mg N/A Lixisenatide QD; within 60 minutes before breakfast ~2 hours ~3 hours 10 µg (2 weeks) 20 µg Renal Byetta [package insert]. 2015. Victoza [package insert]. 2015. Bydureon [package insert]. 2015. Gilbert MP, et al. Am J Med. 2009;122(suppl 6):S11-S24. Bischoff LA, et al. Expert Opin Pharmacother. 2011;12(8):1297-1303. St Onge EL, et al. Expert Opin Biol Ther. 2010;10(5):801-6. Umpierrez GE, et al. Diabetes Obes Metab. 2011;13(5):418-425. Christensen M, et al. Expert Opin Investig Drugs. 2011;20(4):549-557. Pharmacokinetic Profile of Currently Available Basal Insulins Plasma Insulin Levels Intermediate (NPH) Long (detemir) Long (U 100 glargine) Ultra long (degludec & glargine U 300) 4 6 8 10 2 14 18 22 0 12 16 20 24 26 28 30 32 34 36 Time (hr) Hirsch IB. N Engl J Med. 2005; 352:174 83. Flood TM. J Fam Pract. 2007; 56(suppl 1):S1 S12. Becker RH et al. Diabetes Care. 2015; 38:637 43. Insulin Comparison Insulin Onset (hr) Peak (hr) Duration (hr) Appearance Insulin Lispro U100 & U200 within 15 min 0.5-1.5 3-5 Clear Insulin Aspart within 15 min 1-3 3-5 Clear Insulin Glulisine 0.25-0.5 0.5-1 4 Clear Regular U100 0.5 1 2-4 5-8 Clear Regular inhaled Within 5 min 20-40 minutes 3 Powder Regular U-500 30 min 2-4 Up to 24 hr Clear NPH 1-2 4-10 14+ Cloudy Insulin Detemir 3-4 6-8 (though relatively flat) up to 20-24 Clear Insulin Glargine U100 1.5 flat 24 Clear Insulin Glargine U300 1.5 flat 26 Clear Insulin Degludec U100 & U200 0.5 1 flat >30 Clear Lispro Mix 50/50 0.25-0.5 0.5-3 14-24 Cloudy Lispro Mix 75/25 0.25-0.5 0.5-2.5 14-24 Cloudy Aspart Mix 70/30 0.1-0.2 1-4 18-24 Cloudy Degludec/aspart Mix 70/30 0.23 1.2 2.3 >24 Cloudy Note: Patient specific onset, peak, duration may vary from times listed in table, Peak and duration are often very dose dependent with shorter duration of actions with smaller doses and vice versa 18
Weight Effect Hypoglycemia β-cell Protection CVD Benefits Cost Other Considerations GI adverse effects (gas), AGIs Neutral Low risk Possible Possible $ to $$ dose frequency GI adverse effects (nausea), Amylinomimetic Loss Low risk Possible Yes $$ injectable, dose frequency Bile acid Neutral GI adverse effects (constipation), Low risk Possible Yes $$ sequestrant or loss dose frequency GI adverse effects (diarrhea), Biguanides Loss Low risk Possible Yes $ renal and hepatic impairment DPP-4 inhibitors Neutral Low risk Possible Yes $$$ Minimal adverse effects (gliptins) Neutral GI adverse effects (nausea), Dopamine agonist Low risk Unknown Yes/no $$$ or loss hypotension, dizziness GLP-1 agonists Loss Low risk Possible Yes $$$ GI adverse effects (nausea), injectable Insulin Gain or loss Risk bolus Low risk basal Possible Possible $ to $$ Injectable, dose frequency (bolus), increased SMBG Secretagogues sulfonylureas and glinides Gain Risk No No $ to $$ Immediate short-term response, increased SMBG, dose frequency (glinides) SGLT-2 inhibitors Loss Low risk?? Yes $$$ TZDs (glitazones) Gain Low risk Possible Yes/no $$ Urinary tract and urogenital infections 4-8 weeks for response, redistribution of SC/visceral fat, edema, bone loss, fracture, bladder cancer FPG = fasting plasma glucose; PPG = postprandial glucose; GI = gastrointestinal; SMBG = self-monitoring of blood glucose. Unger J, et al. Postgrad Med. 2010;122(3):145-157. Cornell S, et al. Postgrad Med. 2012;124(4):84-94. Key Points Metformin is recommended as initial therapy for most patients with type 2 diabetes, but most patients require additional therapy, particularly as the disease progresses. Guidelines recommend several second line treatment options including insulin, sulfonylureas, thiazolidinediones, DPP 4 inhibitors, GLP 1 agonists, and SGLT 2 inhibitors. A patient centered approach to decision making is recommended including an evaluation of the mechanism of action, efficacy, unique benefits and safety of each option. 19